vs
Encompass Health Corp（EHC）与维谛技术（VRT）财务数据对比。点击上方公司名可切换其他公司
维谛技术的季度营收约是Encompass Health Corp的1.7倍（$2.6B vs $1.5B），维谛技术净利率更高（14.7% vs 9.5%，领先5.3%），维谛技术同比增速更快（30.1% vs 9.9%），维谛技术自由现金流更多（$652.8M vs $116.7M），过去两年维谛技术的营收复合增速更高（16.5% vs 8.3%）
Encompass Health Corp前身为Amcare及HealthSouth，总部位于美国阿拉巴马州伯明翰，是美国规模最大的住院康复服务提供商，在39个州及波多黎各拥有173家住院康复医院，为中风、神经系统疾病、心肺病症、脑损伤等患者提供专业康复诊疗服务。
维谛技术（Vertiv）是一家美国跨国企业，专注于为数据中心、通信网络、商业及工业场景提供关键基础设施及配套服务，旗下方案可有效保障各行业客户关键业务系统的稳定高效运行。
EHC vs VRT — 直观对比
营收规模更大
VRT
是对方的1.7倍
$1.5B
营收增速更快
VRT
高出20.2%
9.9%
净利率更高
VRT
高出5.3%
9.5%
自由现金流更多
VRT
多$536.1M
$116.7M
两年增速更快
VRT
近两年复合增速
8.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.5B | $2.6B |
| 净利润 | $146.1M | $390.1M |
| 毛利率 | — | 37.7% |
| 营业利润率 | 16.7% | — |
| 净利率 | 9.5% | 14.7% |
| 营收同比 | 9.9% | 30.1% |
| 净利润同比 | 20.8% | 137.1% |
| 每股收益（稀释后） | $1.43 | $0.99 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EHCVRT
| Q1 26 | — | $2.6B | ||
| Q4 25 | $1.5B | $2.9B | ||
| Q3 25 | $1.5B | $2.7B | ||
| Q2 25 | $1.5B | $2.6B | ||
| Q1 25 | $1.5B | $2.0B | ||
| Q4 24 | $1.4B | $2.3B | ||
| Q3 24 | $1.4B | $2.1B | ||
| Q2 24 | $1.3B | $2.0B |
净利润EHCVRT
| Q1 26 | — | $390.1M | ||
| Q4 25 | $146.1M | $445.6M | ||
| Q3 25 | $126.5M | $398.5M | ||
| Q2 25 | $142.1M | $324.2M | ||
| Q1 25 | $151.5M | $164.5M | ||
| Q4 24 | $120.9M | $147.0M | ||
| Q3 24 | $108.2M | $176.6M | ||
| Q2 24 | $114.1M | $178.1M |
毛利率EHCVRT
| Q1 26 | — | 37.7% | ||
| Q4 25 | — | 38.9% | ||
| Q3 25 | — | 37.8% | ||
| Q2 25 | — | 34.0% | ||
| Q1 25 | — | 33.7% | ||
| Q4 24 | — | 37.1% | ||
| Q3 24 | — | 36.5% | ||
| Q2 24 | — | 38.0% |
营业利润率EHCVRT
| Q1 26 | — | — | ||
| Q4 25 | 16.7% | 20.1% | ||
| Q3 25 | 14.9% | 19.3% | ||
| Q2 25 | 16.2% | 16.8% | ||
| Q1 25 | 16.4% | 14.3% | ||
| Q4 24 | 14.3% | 19.5% | ||
| Q3 24 | 13.6% | 17.9% | ||
| Q2 24 | 14.3% | 17.2% |
净利率EHCVRT
| Q1 26 | — | 14.7% | ||
| Q4 25 | 9.5% | 15.5% | ||
| Q3 25 | 8.6% | 14.9% | ||
| Q2 25 | 9.7% | 12.3% | ||
| Q1 25 | 10.4% | 8.1% | ||
| Q4 24 | 8.6% | 6.3% | ||
| Q3 24 | 8.0% | 8.5% | ||
| Q2 24 | 8.8% | 9.1% |
每股收益（稀释后）EHCVRT
| Q1 26 | — | $0.99 | ||
| Q4 25 | $1.43 | $1.14 | ||
| Q3 25 | $1.24 | $1.02 | ||
| Q2 25 | $1.39 | $0.83 | ||
| Q1 25 | $1.48 | $0.42 | ||
| Q4 24 | $1.18 | $0.38 | ||
| Q3 24 | $1.06 | $0.46 | ||
| Q2 24 | $1.12 | $0.46 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $72.2M | $2.5B |
| 总债务越低越好 | $2.4B | $0 |
| 股东权益账面价值 | $2.4B | $4.2B |
| 总资产 | $7.1B | $13.4B |
| 负债/权益比越低杠杆越低 | 1.00× | 0.00× |
8季度趋势，按日历期对齐
现金及短期投资EHCVRT
| Q1 26 | — | $2.5B | ||
| Q4 25 | $72.2M | $1.7B | ||
| Q3 25 | $48.7M | $1.4B | ||
| Q2 25 | $99.1M | $1.6B | ||
| Q1 25 | $95.8M | $1.5B | ||
| Q4 24 | $85.4M | $1.2B | ||
| Q3 24 | $147.8M | $908.7M | ||
| Q2 24 | $154.4M | $579.7M |
总债务EHCVRT
| Q1 26 | — | $0 | ||
| Q4 25 | $2.4B | $2.9B | ||
| Q3 25 | $2.4B | $2.9B | ||
| Q2 25 | $2.3B | $2.9B | ||
| Q1 25 | $2.3B | $2.9B | ||
| Q4 24 | $2.4B | $2.9B | ||
| Q3 24 | $2.3B | $2.9B | ||
| Q2 24 | $2.7B | $2.9B |
股东权益EHCVRT
| Q1 26 | — | $4.2B | ||
| Q4 25 | $2.4B | $3.9B | ||
| Q3 25 | $2.4B | $3.5B | ||
| Q2 25 | $2.3B | $3.1B | ||
| Q1 25 | $2.2B | $2.7B | ||
| Q4 24 | $2.1B | $2.4B | ||
| Q3 24 | $2.0B | $1.8B | ||
| Q2 24 | $1.8B | $1.5B |
总资产EHCVRT
| Q1 26 | — | $13.4B | ||
| Q4 25 | $7.1B | $12.2B | ||
| Q3 25 | $6.9B | $10.8B | ||
| Q2 25 | $6.8B | $10.4B | ||
| Q1 25 | $6.6B | $9.5B | ||
| Q4 24 | $6.5B | $9.1B | ||
| Q3 24 | $6.5B | $8.9B | ||
| Q2 24 | $6.4B | $8.1B |
负债/权益比EHCVRT
| Q1 26 | — | 0.00× | ||
| Q4 25 | 1.00× | 0.74× | ||
| Q3 25 | 1.01× | 0.83× | ||
| Q2 25 | 1.02× | 0.93× | ||
| Q1 25 | 1.08× | 1.10× | ||
| Q4 24 | 1.14× | 1.20× | ||
| Q3 24 | 1.20× | 1.62× | ||
| Q2 24 | 1.46× | 1.91× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $346.0M | — |
| 自由现金流经营现金流 - 资本支出 | $116.7M | $652.8M |
| 自由现金流率自由现金流/营收 | 7.6% | 24.6% |
| 资本支出强度资本支出/营收 | 14.8% | 4.2% |
| 现金转化率经营现金流/净利润 | 2.37× | — |
| 过去12个月自由现金流最近4个季度 | $439.2M | $2.3B |
8季度趋势，按日历期对齐
经营现金流EHCVRT
| Q1 26 | — | — | ||
| Q4 25 | $346.0M | $978.9M | ||
| Q3 25 | $270.8M | $508.7M | ||
| Q2 25 | $270.2M | $322.9M | ||
| Q1 25 | $288.6M | $303.3M | ||
| Q4 24 | $278.8M | $425.2M | ||
| Q3 24 | $267.8M | $378.2M | ||
| Q2 24 | $217.4M | $378.4M |
自由现金流EHCVRT
| Q1 26 | — | $652.8M | ||
| Q4 25 | $116.7M | $885.6M | ||
| Q3 25 | $83.7M | $463.5M | ||
| Q2 25 | $113.3M | $277.9M | ||
| Q1 25 | $125.5M | $266.8M | ||
| Q4 24 | $80.1M | $364.5M | ||
| Q3 24 | $120.3M | $341.8M | ||
| Q2 24 | $60.5M | $344.3M |
自由现金流率EHCVRT
| Q1 26 | — | 24.6% | ||
| Q4 25 | 7.6% | 30.8% | ||
| Q3 25 | 5.7% | 17.3% | ||
| Q2 25 | 7.8% | 10.5% | ||
| Q1 25 | 8.6% | 13.1% | ||
| Q4 24 | 5.7% | 15.5% | ||
| Q3 24 | 8.9% | 16.5% | ||
| Q2 24 | 4.6% | 17.6% |
资本支出强度EHCVRT
| Q1 26 | — | 4.2% | ||
| Q4 25 | 14.8% | 3.2% | ||
| Q3 25 | 12.7% | 1.7% | ||
| Q2 25 | 10.8% | 1.7% | ||
| Q1 25 | 11.2% | 1.8% | ||
| Q4 24 | 14.1% | 2.6% | ||
| Q3 24 | 10.9% | 1.8% | ||
| Q2 24 | 12.1% | 1.7% |
现金转化率EHCVRT
| Q1 26 | — | — | ||
| Q4 25 | 2.37× | 2.20× | ||
| Q3 25 | 2.14× | 1.28× | ||
| Q2 25 | 1.90× | 1.00× | ||
| Q1 25 | 1.90× | 1.84× | ||
| Q4 24 | 2.31× | 2.89× | ||
| Q3 24 | 2.48× | 2.14× | ||
| Q2 24 | 1.91× | 2.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EHC
| Medicare | $1.0B | 66% |
| Medicare Advantage | $243.1M | 16% |
| Managed Care | $160.7M | 10% |
| Medicaid | $47.0M | 3% |
| Other Income Source | $44.8M | 3% |
| Other Thirdparty Payors | $11.2M | 1% |
| Workers Compensation | $7.6M | 0% |
| Patients | $4.6M | 0% |
VRT
暂无分部数据
